$Halozyme Therapeutics (HALO.US)$Revenue plummeted by half t...
$Halozyme Therapeutics (HALO.US)$Revenue plummeted by half to 0.15 billion in 2018, then rapidly increased to 0.44 billion over the next three years. Operating profit turned around in 2020 to reach 0.14 billion, and in 2021, it reached 0.28 billion. Net income reached 0.13 billion in 2020 and 0.4 billion in 2021.
Revenue increased by 40% to reach 0.48 billion in the first three quarters of 2022, but due to a significant increase in expenses, operating profit decreased by 12%, and net income fell by 57% to 0.144 billion.
The current P/E ratio is 18.4, with a TTM P/E ratio already at 34. It seems that the full-year results will not be too good, and it is currently not attractive.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
